Benitec Biopharma Inc. · NASDAQ:BNTC

Benitec Biopharma — Investor Presentation (November 2016)

20 slides from Benitec Biopharma's investor presentation, November 2016

1. Slide 1: Corporate Presentation November 2016

   NASDAQ: BNTC ASX: BLT Corporate Presentation November 2016 Copyright © Benitec Biopharma Ltd www.benitec.com

2. Slide 2: Safe Harbor Statement

   Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Benitec has tried to identify such forward-looking statements by use of such words as "expects,"

3. Slide 3: Company overview

   Company overview NOVEL GENE SILENCING ddRNAi combines RNAi with gene therapy delivery to change the way PLATFORM patients are treated and cured for unmet human therapeutic needs Programs in indications with high unmet clinical need or large patient FOCUSED PIPELINE populations such as hepatitis B, O

4. Slide 4: Gene therapy approach to silence disease-associated genes

   Gene therapy approach to silence disease-associated genes Copyright © Benitec Biopharma Ltd www.benitec.com

5. Slide 5: Benitec technology: DNA-directed RNAi

   Benitec technology: DNA-directed RNAi Benitec technology • Combines RNA interference with siRNA ddRNAi gene therapy delivery • Long term therapeutic potential from a single administration • Steady state levels of shRNA expression • Silence a single gene or target multiple genes simultaneously • Sile

6. Slide 6: Business Model

   Business Model ddRNAi Platform Pipeline Business Outcomes Partnering of Pipeline programs (e.g. co-develop or license) Prioritising ddRNAi pipeline Internal Product opportunities by: Pipeline Product Franchise spinout and/or - identifying unmet medical needs commercialisation -optimised delivery -va

7. Slide 7: Pipeline Programs

   Pipeline Programs IND- Program Discovery Preclinical Phase I/II Status Enabling Oncology Head and Neck • Subject to sub-license agreement with NantVentures Cancer • Clinical POC completed RNA antisense program • Follow on PII/III trial design under review Head and Neck Cancer • To be initiated in Q1

8. Slide 8: New ddRNAi Applications

   New ddRNAi Applications IND- Program Discovery Preclinical Phase I/II Phase III Status Enabling Cell Therapy Stem Cells • Program terminated Immunotherapy CAR-T • In vitro POC underway New Technologies Non-Viral Delivery • In vitro POC underway Copyright © Benitec Biopharma Ltd 8 www.benitec.com

9. Slide 9: Out-licensed Programs

   Out-licensed Programs Product Focus Indication Company Discovery Preclinical Phase I/IIa Candidate Infectious HIV/AIDs Cal-1 Calimmune Disease Cancer Cancer dCellVax Regen Biopharma Immunotherapy Ocular Retinitis Spark RhoNova Disease Pigmentosa Therapeutics Genetic Huntington’s uniQure Disease Dise

10. Slide 10: Global IP portfolio

    Global IP portfolio Robust Global IP Portfolio ddRNAi Technology (CSIRO Licensed) Pipeline IP Portfolio (Benitec Owned) • International coverage for ddRNAi platform • Target indications, product candidates, technology technology improvements • 30 Granted Patents (in-licensed) • 32 Granted Patents (o

11. Slide 11: Strategic Collaboration with NantVentures

    Strategic Collaboration with NantVentures Copyright © Benitec Biopharma Ltd www.benitec.com

12. Slide 12: Strategic Engagement With NantVentures

    Strategic Engagement With NantVentures Highlights: • Two phased investment with oncology focused R&D collaboration • Returns Benitec to the clinic through in-licensing of a Phase II/III gene silencing asset for the treatment of squamous cell carcinoma associated with the head and neck (SCCHN) • Foll

13. Slide 13: Deal Structure and Mechanics

    Deal Structure and Mechanics Two tranche investment structure: First Tranche:First Tranche Second Tranche • Placement of 19.99% issued shares to • Issue of up to additional 29.3m shares to NantCapital LLC (29.3m shares at NantCapital subject to shareholder $0.0895 per share) approval (AGM 14th Decem

14. Slide 14: Nant's Vision and Focus

    Nant’s Vision and Focus ‘The Cognitive Age’: Convergence of Science, Technology and Communication • Nantworks: founded by Patrick Soon Shiong in 2011 • Shiong is pioneer of novel therapies for diabetes and cancer (e.g. Abraxane) and prolific innovator • Ecosystem of companies to create transformativ

15. Slide 15: Framework for Research Collaboration

    Framework for Research Collaboration Gene silencing treatments directed against squamous cell carcinoma associated with head and neck (SCCHN) targeting epidermal growth factor receptor (EGFR) Sublicense of RNA antisense program ddRNAi Program: a second generation for the purpose of initiating a foll

16. Slide 16: Corporate and Financial

    Corporate and Financial Copyright © Benitec Biopharma Ltd www.benitec.com

17. Slide 17: Company financial snapshot

    Company financial snapshot ASX: BLT Key Financial Details NASDAQ: BNTC NASDAQ: BNTCW BLT Share Price as of 28th Oct, 2016: AUD 11 cents Market Capitalisation as of 28th Oct, 2016: AUD 19.3M Issued Securities as of 30 June, 2016: Ordinary shares 175,834,915 Options 36,366,203 Cash Balance as of 30 Se

18. Slide 18: Management team

    Management team Greg West • Former CFO of Benitec Biopharma, 10 years biotech experience Chief Executive Office • Prior roles at PriceWaterhouse, Bankers Trust, Deutsche Bank and NZI Dr. Cliff Holloway • Former CEO and MD of Sienna Cancer Diagnostics, and Chief Business and Operating Officer Bioscep

19. Slide 19: Board of Directors

    Board of Directors Peter Francis • Partner at Francis Abourizk Lightowlers Lawyers Chairman • Director at Optiscan Imaging Ltd, Former Director, Xceed Capital (Melbourne, AU) Megan Boston • Acting Chair at Adult Multicultural and Education Service Director • Chair of Audit and Risk Committee for Vic

20. Slide 20: NASDAQ: BNTC ASX: BLT

    NASDAQ: BNTC ASX: BLT Copyright © Benitec Biopharma Ltd www.benitec.com

Benitec Biopharma — Investor Presentation (November 2016) on 6ix